Pretreatment by Rad51-inhibitory substances such as gemcitabine followed by arterial chemotherapy using antineoplastic agents causing DNA, DSB, or DNA crosslink might be more beneficial for patients with locally advanced pancreatic cancers than conventional treatments. This evidence concerns the gene RAD51 and pancreatic neoplasm.